
Experimental
Control
Risk Ratio
Risk Ratio
Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% CI
M-H, Fixed, 95% CI
3.1.1 Anti-VEGF therapy vs Sham
MYRROR 2014 35 90 3 31 100.0% 4.02 [1.33, 12.15]
Subtotal (95% CI) 90 31 100.0% 4.02 [1.33, 12.15]
Total events 35 3
Heterogeneity: Not applicable
Test for overall effect: Z = 2.46 (P = 0.01)
3.1.2 Anti-VEGF therapy vs PDT
BRILLIANCE 2019 59 184 15 91 55.5% 1.95 [1.17, 3.23]
Moreno 2013 10 22 4 20 11.6% 2.27 [0.85, 6.11]
Parodi 2010 7 19 1 18 2.8% 6.63 [0.90, 48.69]
RADANCE 2014 50 116 8 55 30.0% 2.96 [1.51, 5.81]
Subtotal (95% CI) 341 184 100.0% 2.42 [1.68, 3.50]
Total events 126 28
Heterogeneity: Chi² = 2.06, df = 3 (P = 0.56); I² = 0%
Test for overall effect: Z = 4.72 (P < 0.00001)
3.1.3 Anti-VEGF monotherapy vs PDT combination therapy
Rinaldi 2016 12 20 13 20 100.0% 0.92 [0.57, 1.49]
Subtotal (95% CI) 20 20 100.0% 0.92 [0.57, 1.49]
Total events 12 13
Heterogeneity: Not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
3.1.4 Anti-VEGF retreatment criteria: VA stabilization vs Disease activity
BRILLIANCE 2019 81 182 75 184 56.7% 1.09 [0.86, 1.39]
RADANCE 2014 56 105 60 116 43.3% 1.03 [0.80, 1.33]
Subtotal (95% CI) 287 300 100.0% 1.07 [0.90, 1.27]
Total events 137 135
Heterogeneity: Chi² = 0.11, df = 1 (P = 0.74); I² = 0%
Test for overall effect: Z = 0.72 (P = 0.47)
0.01
0.1
1
10
100
Favours [experimental]
Favours [control]